Pfizer’s Newest Pick-up: Global Blood Therapeutics and Its Sickle Cell Solutions

Sitting on a massive pile of COVID-19 vaccine cash, pharma powerhouse Pfizer has made it clear that it has enough capital to finance as many strategic acquisitions to diversify its portfolio as it desires. Now, the company is shelling out $5.4 billion in cash to buy out sickle cell disease solutions company Global Blood Therapeutics (GBT)...